Drug Discovery

Our expertise in the area of drug discovery and translational research

The unique research profile of Helmholtz Zentrum München – characterized by its combination of mechanism-based science with state-of-the art biomedical technologies in translational research approaches – enables the further development of innovative diagnostic, therapeutic and preventive methods for clinical applications.

Drug Development

Target Discovery Plattform

Head: Prof. Dr. Matthias Tschöp

Genome-wide lentiviral shRNA library to identify new targets through “loss-of-function” phenotypes.

To the Institute for Diabetes and Obesity (IDO) Website

Assay Development und Screening Plattform

Head: Dr. Kamyar Hadian

Development of innovative and complex cellular and biochemical assays for screening small molecules (protein-protein-interactions, stem cell models and high content screening); evaluation of screening data and further development of internal substance libraries.

Assay Development and Screening Platform

Science-Driven Structure-Based Drug Development

Head: Prof. Michael Sattler

Structural biology of complex targets and inhibitor complexes; NMR / hit validation; fragment-based screening and X-ray crystallography.

To the Structural Biology (STB) Website

Protein Expression and Purification:

Head: Dr. Arie Geerlof

Production, purification and characterization of recombinant proteins.

Protein Expression and Purification Facility

Chemoinformatics

Head: Dr. Igor Tetko

Software development and databases to predict physicochemical properties and absorption, distribution, metabolism, excretion and toxicity (ADMET) characteristics of compounds in silico.

To the Structural Biology (STB) Website


Systems Biology of Small Molecules

Head : Dr. Mónica Campillos González

Development of computer models for understanding the effects of small molecules in biological systems, and identification of new drug targets and new targets for known drugs.

To the Systems Biology of Small Molecules Website

Metabolomic Validation Platform (metDRUG):

Head: Prof. Jerzy Adamski

Metabolomic validation of hits, lead structures and drugs in human cell lines and stem cells; determination of biotolerability of drug candidates on the basis of metabolite profiles.

To the Genome Analysis Center (GAC) Website

In Vivo Models

Head: Prof. Martin Hrabĕ de Angelis

Phenotyping of mouse mutants for drug challenges to analyze the effects and side effects of small molecules in mouse models for human diseases (GMCIII).

To the German Mouseclinic (GMC) Website

Medicinal Chemistry

Director: Prof. Dr. Oliver Plettenburg

Identifying and optimizing innovative drug substances.

To the Institute of Medicinal Chemistry (IMC) website